Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples